Volume 95 Issue 41 | p. 17 | Concentrates
Issue Date: October 16, 2017

Glycoscience firm Palleon launches

Department: Business
Keywords: Oncology, glycoimmune checkpoints, glycoscience, Palleon, immuno-oncology

Waltham, Mass.-based Palleon Pharmaceuticals has launched with $47.6 million in series A funding to develop immuno-oncology drugs based on cancer glycans—the sugar molecules that protrude from tumors and are used to avoid immune system surveillance. The approach is reminiscent of checkpoint inhibitor therapies, which jump-start the immune system’s ability to target tumors, but Palleon’s drugs will take aim at immune cell receptors that get misdirected by tumor glycans. Palleon’s scientific cofounders include Stanford University chemist Carolyn Bertozzi and University of Dundee glycoimmunologist Paul Crocker.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment